Balancing risk and reward: the question of natalizumab.
Hauser
Stephen L
SL
Johnston
S Claiborne
SC
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D039441:Integrin alpha4; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D018570:Risk Assessment
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069442:Natalizumab; D039441:Integrin alpha4